Semaglutide tablets for weight and muscle health in Duchenne muscular dystrophy
Tests oral semaglutide against placebo in people with Duchenne muscular dystrophy and obesity.
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Registry title
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 30 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2030
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Semaglutide (Rybelsus®)
- Placebo
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult men with Duchenne muscular dystrophy (DMD) who are overweight or have obesity. It tests whether oral semaglutide affects muscle mass.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Duchenne muscular dystrophy confirmed by muscle biopsy or genotype. BMI of 30 kg/m2 or more, or BMI of 27 kg/m2 or more with at least one weight-related health condition (for example high blood pressure, type 2 diabetes or high blood fats).
Main reasons for not taking part
- Type 1 diabetes, uncontrolled type 2 diabetes (HbA1c >8% (64 mmol/mol)), or type 2 diabetes needing insulin or sulfonylurea
- History of pancreatitis
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Allergic reaction to semaglutide or its components in the past
- Uncontrolled major depression, a past suicide attempt, other severe psychiatric disorders, PHQ-9 score of 15 or more, or suicidal ideation type 4 or 5 (C-SSRS)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male
- Age ≥18years
- BMI ≥ 30kg/m2 or BMI ≥ 27kg/m2 with at least one weight-related comorbid condition (e.g., hypertension, T2D, or dyslipidemia)
- Clinical phenotype of DMD confirmed with muscle biopsy or genotype
Who cannot take part
- History of pancreatitis
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- History of allergic reaction to semaglutide or medication components
- Contraindication to MRI. If unable to tolerate whole body/cardiac MRI but able to undergo lower extremity MRI, the participant may be invited to complete extremity MRI (Aim 1) and not complete MRI for Aim 2/3 (secondary Aims/outcomes)
- Uncontrolled major depressive disorder, lifetime history of suicide attempt, history of other severe psychiatric disorders (e.g., schizophrenia, bipolar disorder), PHQ-9 score ≥15 or suicidal ideation type 4 or 5 (C-SSRS)
- Type 1 diabetes, uncontrolled type 2 diabetes (HbA1c >8%) or type 2 diabetes requiring the use of insulin or sulfonylurea
- Unable to comply with study procedures or unsafe to complete the study in the opinion of the investigator
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesContact: Jaclyn Tamaroff, MD, MSCITaking people
About the trial
What the trial wants to find out
Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to muscle weakness, breathing difficulties, heart disease, and early death. Approximately half of individuals with DMD have elevated body mass indices (BMIs) in the overweight or obesity range. High BMI is due to a combination of factors including limited mobility and steroid medications, which are used to treat DMD.
Read full original descriptionShow less
There are new medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that promote weight loss in the general population. GLP-1 RAs are approved for weight loss in children and adults and have beneficial effects on the heart. There is a concern that these medications could have unwanted side effects in individuals with DMD, specifically decreasing their muscle mass. While it is important to consider the use weight-loss medications in DMD, the investigators want to ensure that they are safe and well-tolerated. Therefore, this study will systematically evaluate whether the use of GLP-1 RAs in adolescents and young adults with DMD affects muscle mass.
The overall goal of this study is to assess the safety and tolerability of GLP1-RAs in individuals with both DMD and obesity. The primary focus will be on muscle health, but the study will also evaluate activity levels, mood, gastrointestinal symptoms, and quality of life. Secondary goals will be to understand the impact of GLP1-RAs on weight, fat mass, glucose and insulin levels, and heart and lung function in individuals with DMD. The investigators hypothesize that GLP1-RAs will be well-tolerated and will decrease fat mass, without a large decrease in muscle mass.
Participants will:
* Take oral semaglutide or a placebo every day for 24 weeks (randomized controlled trial) * Then take oral semaglutide every day for 40 weeks (open label extension) * Complete in-person study visits at 3 timepoints * Study visits may include: an MRI of the body to evaluate muscle and fat tissue, laboratory testing, a mixed meal tolerance test, questionnaires, an MRI of the heart, pulmonary function tests, and additional measures * Calls with the study team between visits (monthly or every other month)
The 3 groups in the trial
- Semaglutide (RCT)Treatment being tested
oral semaglutide (24 week RCT)
Treatment: Semaglutide (Rybelsus®)
- Placebo (RCT)Placebo, for comparison
oral placebo (24 week RCT)
Treatment: Placebo
- Semaglutide (OLE)Treatment being tested
oral semaglutide (40 week open label extension)
Treatment: Semaglutide (Rybelsus®)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- Plain-language title
- Semaglutide tablets for weight and muscle health in Duchenne muscular dystrophyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026